Clay Siegall is the current President and Chairman of Seattle Genetics, a company he cofounded in 1998. Clay Siegall is an expert in cancer therapies and treatment. Mr. Siegall draws motivation from his passion for his patient’s recovery and the use of current research innovations to develop new drugs to treat cancerous conditions. His strategy involves combining cancer research information, cutting edge technology, and development of medicines to treat even the rarest and incurable types of Lymphoma cancers.
Under his stewardship, Clay Siegall has been able to secure $1.2 billion in public and private funds for future research. Clay Siegall has generated revenue up to$350 million solely from the selling of the Adcentris Drug. The Adcentris drug was developed by Seattle Genetics and is an anti-drug conjugate (ADC) which has since been approved by the FDA.
ADC’s are used in the treatment of lymphoma cancers and is claimed to be capable of treating 70 other diseases. Clay Siegall’s firm has already rolled out trial research centers in various states to test a drug that is currently supposed to be the ultimate cure of Hodgkin Lymphoma. Clay has acquired several multiple licenses for their ADC technology with large pharmaceutical companies such as GlaxoSmithKline.
From 1991 to 1997, Mr. Siegall worked as a Principal Scientist at Bristol- Myers Institute. Siegall previously worked at The National Health Cancer Institute in the years 1989-1991. Clay Siegall sits on several boards of directors including Mirna and Ultragenyx Therapeutics Inc., and the Washington Roundtable.
Clay Siegall has authored over seventy publications, including several Word Press blogs. The latest is an intriguing article on a controversial genetics breakthrough. Mr. Siegall has received numerous awards for his selfless contributions in the field of research; In 2012, Siegall was awarded the Pacific Northwest Entrepreneur of the Year by Ernst and Young in 2012 and 2013 the University of Maryland recognized Clay Siegall as the Alumnus of the year in mathematics and computer informatics. Clay Siegall also has 15 registered patents.
He is a Zoology graduate from Maryland University and holds a Genetics Ph.D., from The George Washington University.